
1. malar j. 2017 jan 9;16(1):23. doi: 10.1186/s12936-016-1663-1.

absence vivo selection k13 mutations artemether-lumefantrine
treatment uganda.

balikagala b(1), mita t(2), ikeda m(3), sakurai m(4), yatsushiro s(5), takahashi 
n(4), tachibana si(3), auma m(6), ntege eh(1), ito d(1), takashima e(1), palacpac
nm(7), egwang tg(8), onen jo(9), kataoka m(5), kimura e(7), horii t(7), tsuboi
t(10).

author information: 
(1)division malaria research, proteo-science center, ehime university, 3
bunkyo-cho, matsuyama, ehime, 790-8577, japan.
(2)department molecular cellular parasitology, school medicine,
juntendo university, tokyo, 113-8421, japan. tmita@juntendo.ac.jp.
(3)department molecular cellular parasitology, school medicine,
juntendo university, tokyo, 113-8421, japan.
(4)department international affairs tropical medicine, school medicine,
tokyo women's medical university, tokyo, japan.
(5)health research institute, national institute advanced industrial science
and technology (aist), takamatsu, japan.
(6)st. mary's hospital lacor, gulu, uganda.
(7)department molecular protozoology, research institute microbial
diseases, osaka university, suita, japan.
(8)med biotech laboratories, kampala, uganda.
(9)department biology, faculty science, gulu university, gulu, uganda.
(10)division malaria research, proteo-science center, ehime university, 3
bunkyo-cho, matsuyama, ehime, 790-8577, japan. tsuboi.takafumi.mb@ehime-u.ac.jp.

background: individual drug treatment may select resistant parasites human
body, process termed vivo selection. single nucleotide polymorphisms in
plasmodium falciparum chloroquine-resistance transporter (pfcrt) multidrug
resistance gene 1 (pfmdr1) genes reportedly selected after
artemether-lumefantrine treatment. however, paucity data regarding 
in vivo selection p. falciparum kelch propeller domain (pfkelch13)
polymorphisms, responsible artemisinin-resistance asia, six putative
background mutations artemisinin resistance; d193y ferredoxin, t484i in
multiple resistance protein 2, v127m apicoplast ribosomal protein s10, i356t
in pfcrt, v1157l protein phosphatase c1484f phosphoinositide-binding
protein.
methods: artemether-lumefantrine efficacy study follow-up period of
28 days conducted northern uganda 2014. above-mentioned genotypes
were comparatively analysed drug administration days; 3, 7, and
28 days treatment.
results: 61 individuals successful follow-up, artemether-lumefantrine
treatment regimen effective pcr adjusted efficacy 95.2%. among
146 isolates obtained treatment, wild-type alleles observed 98.6% 
of isolates pfkelch13 isolates six putative background genes
except i356t pfcrt, 2.4% isolates mixed infections. vivo
selection study revealed isolates detected follow-up period
harboured wild type alleles pfkelch13 six background genes.
conclusion: mutations pfkelch13 six background genes may play an
important role vivo selection artemether-lumefantrine treatment
in uganda. different mechanisms might rather associated existence 
parasites treatment.

doi: 10.1186/s12936-016-1663-1 
pmcid: pmc5223472
pmid: 28068997  [indexed medline]

